Article 9 of 10

Patterns in Other Places

Four countries, four institutional answers

The case at the centre of this project is not isolated. Four countries have examined the same class of drugs, reaching different conclusions. This article does not present them as a cumulative case.

Canada Inconclusive

During the 1992–93 deployment to Somalia, Canadian soldiers were required to take mefloquine under an improperly conducted trial. An inquiry was cut short in 1997. Health Canada's 2017 review found no conclusive evidence of long-lasting, permanent effects.

United Kingdom Policy response

The Commons Defence Committee's 2016 report led to a last-resort prescribing policy. Prescribing has since fallen to roughly 0.1% of all anti-malarials issued.

United States Contested

In 2002, four Army spouses died at Fort Bragg within roughly six weeks; at least three husbands had taken mefloquine. The investigating panel rated the drug an unlikely factor, attributing the cluster to marital stress and deployment.

Note: The Quinism Foundation, which has called for mefloquine exposure screening under the PACT Act, is directed by Dr Remington Nevin — the researcher whose framework Articles 3 and 4 examine, and who has served as an expert witness in anti-malarial litigation.

Australia Split position

A 2018 Senate inquiry stated it could not make findings on medical causation. The Repatriation Medical Authority declined to recognise the injury as compensable. Yet Australia's Department of Veterans' Affairs recognises these drugs as associated with several conditions and operates a dedicated claims line.

What the pattern actually shows

In every case, the question asked was whether the drug harmed the person who took it. No inquiry in any of the four countries examined effects on households, let alone the communities around them.

← Previous: The Gap, Stated Precisely Next: What a Community Can Do →